Salimon M, Chapelle N, Matysiak-Budnik T, Mosnier JF, Frampas E, Touchefeu Y. Esophageal metastasis of stem cell-subtype hepatocholangiocarcinoma: Rare presentation of a rare tumor. World J Gastroenterol 2018; 24(7): 870-875 [PMID: 29467557 DOI: 10.3748/wjg.v24.i7.870]
Corresponding Author of This Article
Yann Touchefeu, MD, PhD, Doctor, Institut des Maladies de l’Appareil Digestif, Nantes University Hospital, 1 Place Alexis Ricordeau, Nantes 44000, France. yann.touchefeu@chu-nantes.fr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 21, 2018; 24(7): 870-875 Published online Feb 21, 2018. doi: 10.3748/wjg.v24.i7.870
Esophageal metastasis of stem cell-subtype hepatocholangiocarcinoma: Rare presentation of a rare tumor
Maëva Salimon, Nicolas Chapelle, Tamara Matysiak-Budnik, Jean-François Mosnier, Eric Frampas, Yann Touchefeu
Maëva Salimon, Nicolas Chapelle, Tamara Matysiak-Budnik, Yann Touchefeu, Institut des Maladies de l’Appareil Digestif, Nantes University Hospital, Nantes 44000, France
Jean-François Mosnier, Department of Pathology, Nantes University Hospital, Nantes 44000, France
Eric Frampas, Department of Radiology, Nantes University Hospital, Nantes 44000, France
Author contributions: Salimon M and Touchefeu Y designed the research; Salimon M, Chapelle N, Mosnier JF and Frampas E performed the research; Salimon M, Matysiak-Budnik T and Touchefeu Y wrote the paper.
Informed consent statement: This is a non-interventional report; the patient died before the writing of the report. The report is in accordance of the Declaration of Helsinki and its latter amendments.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yann Touchefeu, MD, PhD, Doctor, Institut des Maladies de l’Appareil Digestif, Nantes University Hospital, 1 Place Alexis Ricordeau, Nantes 44000, France. yann.touchefeu@chu-nantes.fr
Telephone: +33-240-083152 Fax: +33-240-083154
Received: December 12, 2017 Peer-review started: December 12, 2017 First decision: December 27, 2017 Revised: January 2, 2018 Accepted: January 16, 2018 Article in press: January 16, 2018 Published online: February 21, 2018
Abstract
Hepatocholangiocarcinoma (cHCC-ICC) is a rare primary hepatic tumor defined by the presence of histological features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Its prevalence ranges from 1%-5% of all primary liver cancers. We report the case of a 55-year-old cirrhotic male patient admitted to our university hospital for dysphagia, revealing a 10 cm lower-third esophageal metastasis of an unresectable cHCC-ICC with stem-cell features. Computed tomography and abdominal magnetic resonance imaging scans revealed multiple hepatic lesions combining features of both HCC and ICC, associated with synchronous bone metastasis. Histological and immunohistochemical analyses of biopsies from the esophageal lesion and the hepatic tumor confirmed the diagnosis of cHCC-ICC with a stem cell-subtype, according to the World Health Organization classification. After a multidisciplinary meeting, the patient was treated with chemotherapy. He received two cycles of a gemcitabine plus cisplatin regimen before bone progression, and he died 3 mo after the initial diagnosis.
Core tip: Hepatocholangiocarcinoma (cHCC-ICC) represents less than 5% of all hepatic tumors and remains an uncommon cancer, with no guidelines concerning its management. Esophageal metastasis is a rare presentation of hepatic tumors. To our knowledge, this case report is the first to describe an esophageal lesion revealing a metastatic stem cell-subtype cHCC-ICC.
